Introduction
Recently, 18 F-NaF has been introduced for imaging of skeletal metastases in various oncologic patients. Several studies have demonstrated the diagnostic properties of 18 F-NaF PET/CT for bone metastasis. Fluoride ions exchange with hydroxy groups in hydroxyapatite crystal bone to form fluoroapatite, which makes 18 F-NaF a highly sensitive bone-seeking PET tracer to detect active bone formation and mineralization. Soft tissue calcifications that may be caused by tumoral necrosis, vascular, infectious or traumatic processes can demonstrate 18 F-NaF uptake utilizing the same mechanism. Clinical interest in 18 F-NaF PET/CT in view of its higher accuracy demonstrated by recent comparative studies has increased. In this regard, it is likely that nonosseous findings, particularly soft tissue metastases, will be encountered more frequently.
Case Report
A 56-year-old female patient with newly diagnosed breast cancer underwent 18 F-FDG PET/CT (FDG-PET), which demonstrated uptake in the primary tumoral lesion at the right breast and ipsilateral metastatic axillary lymph nodes. FDG-PET was performed following the second cycle of neoadjuvant chemotherapy and demonstrated near complete response to therapy (Fig. 1) . However, following the fourth cycle of neoadjuvant chemotherapy, she underwent 18 F-NaF PET/CT because of suspected bone metastasis presenting as back pain. 18 F-NaF-avid metastases in the vertebrae and the sternum and nonosseous 18 F-NaF uptake in the left frontal lobe of the cerebrum were observed (Fig. 2) . The CT counterpart of the image demonstrated a hypodense 12×13-mm area with no visible calcification. The interpretation suggested tumoral necrosis. Nonosseous findings were also observed in CT images including pulmonary metastases and local recurrence of the breast cancer with no 18 F-NaF uptake (Fig. 2) . Further evaluation with FDG-PET (Fig. 3) revealed hypermetabolism in the lesions except for the brain metastasis. Tcbased bone scans; however, with the increasing use of 18 FNaF PET/CT in routine clinical practice for skeletal imaging in oncology [2, 3] , nonosseous uptake is likely to be more frequently encountered. In our case, 18 F-NaF PET/CT was F-NaF PET/CT revealed a metastatic pulmonary lesion (b) and hypermetabolic metastatic lymph nodes (c). Note the diminished FDG uptake (d) on the right frontal lobe lesion, which showed focal uptake on performed because of back pain and successfully revealed bone metastases. In addition, 18 F-NaF uptake was observed at the metastatic cerebral lesion. However, the CT counterpart of the image did not demonstrate any calcification, which suggests cellular-level microscopic calcifications. Soft tissue calcific metastases concentrating bisphosphonates have been reported previously [4] , and similar reports are also evident with 18 F-NaF [5] [6] [7] . Nonosseous uptake of 18 F-NaF due to heterotrophic ossification, brain metastases, metastatic lymph nodes [6] and liver metastasis [7] , as well as atherosclerosis [8] , has been reported. Evaluation of CT images of our patient also revealed metastatic axillary lymph nodes and pulmonary nodules that were not present in the patient's previous FDG-PET images. In this regard, in order to evaluate disease recurrence, the patient underwent FDG-PET, which revealed pulmonary metastases, local recurrence in the breast and metastatic lymph nodes. CT images help with accurate lesion localization and also provide a large amount of diagnostic information. Therefore, previously undetected, clinically significant nonosseous findings in the 18 F-NaF PET/CT may have an impact on the treatment planning.
In conclusion, routine and careful reviewing of nonosseous uptake in 18 F-NaF PET/CT as well as the CT portion is necessary since unexpected extra diagnostic information can alter the disease course.
